Omadacycline (Paratek Pharmaceuticals) is the first agent of the aminomethycyclines class of antibiotics. The drug, which is a semisynthetic derivative of the tetracycline minocycline, exerts its antibacterial effect by binding to the tetracycline binding sites on bacterial ribosomes, leading to the inhibition of bacterial protein synthesis. Omadacycline has an antibacterial spectrum that covers a range of Gram-positive and Gram-negative bacterial pathogens. It has demonstrated potent in vitro activity against a number of significant respiratory pathogens such as Streptococcus pneumonia, Haemophilus influenzae, and Moraxella catarrhalis. The drug was also active against bacterial strains with tetracycline and penicillin resistance.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 omadacycline : Community-acquired pneumonia
LIST OF FIGURES
6 Figure 1: Omadacycline – development overview
7 Figure 2: Omadacycline for community-acquired pneumonia – SWOT analysis
8 Figure 3: Datamonitor Healthcare’s drug assessment summary of omadacycline in community-
9 Figure 4: Datamonitor Healthcare’s drug assessment summary of omadacycline in community-
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.